{"transactions":[{"id":1384928,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":5287303,"ownership":{"direct":false,"nature":"By Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Northpond Ventures, LP (\"Northpond Fund I\"). Northpond Ventures GP, LLC (\"Northpond GP I\") is the general partner of Northpond Fund I, and Michael P. Rubin is the managing member of Northpond GP I. As a result, each of Northpond GP I and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund I. Each of Northpond GP I and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":471415},"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384927,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":11251624,"ownership":{"direct":false,"nature":"By Northpond Ventures II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Northpond Ventures II, LP (\"Northpond Fund II\").  Northpond Ventures II GP, LLC (\"Northpond II GP\") is the general partner of Northpond Fund II, and Michael P. Rubin is the managing member of Northpond II GP. As a result, each of Northpond II GP and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond II GP and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1003193},"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384926,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":763636,"price":11,"value":8399996.0,"ownership":{"direct":false,"nature":"By Northpond Ventures III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Northpond Ventures III, LP (\"Northpond Fund III\").  Northpond Ventures III GP, LLC (\"Northpond III GP\") is the general partner of Northpond Fund III, and Michael P. Rubin is the managing member of Northpond III GP. As a result, each of Northpond III GP and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III GP and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":763636,"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384925,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":471415,"ownership":{"direct":false,"nature":"By Northpond Ventures, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Northpond Ventures, LP (\"Northpond Fund I\"). Northpond Ventures GP, LLC (\"Northpond GP I\") is the general partner of Northpond Fund I, and Michael P. Rubin is the managing member of Northpond GP I. As a result, each of Northpond GP I and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund I. Each of Northpond GP I and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":471415,"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384924,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1003193,"ownership":{"direct":false,"nature":"By Northpond Ventures II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Northpond Ventures II, LP (\"Northpond Fund II\").  Northpond Ventures II GP, LLC (\"Northpond II GP\") is the general partner of Northpond Fund II, and Michael P. Rubin is the managing member of Northpond II GP. As a result, each of Northpond II GP and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond II GP and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":1003193,"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1648609,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":1,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":2,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":3,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series B Preferred Stock","published_at":"2024-02-12T17:51:02.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":12767776,"ownership":{"direct":false,"nature":"By: Northpond Ventures III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures III GP, LLC (\"Northpond III LLC\") is the general partner of Northpond Ventures III, LP (\"Northpond Fund III\"), and Michael P. Rubin is the managing member of Northpond III LLC.  As a result, each of Northpond III LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2805426},"source":{"system":"sec-edgar","filing":"0000950170-24-014000","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1867627/000095017024014000/ownership.xml","form_type":"4"}},{"id":1648608,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":1,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":2,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":3,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2024-02-12T17:51:02.000Z","date":"2024-02-12","kind":"purchase","planned":false,"acquired":true,"shares":450000,"price":22,"value":9900000.0,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP, LLC (\"Northpond LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond LLC.  As a result, Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Mr. Rubin disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein, if any."}],"balance_after":450000,"source":{"system":"sec-edgar","filing":"0000950170-24-014000","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1867627/000095017024014000/ownership.xml","form_type":"4"}},{"id":1648607,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":1,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":2,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":3,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2024-02-12T17:51:02.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":2805426,"ownership":{"direct":false,"nature":"By: Northpond Ventures III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures III GP, LLC (\"Northpond III LLC\") is the general partner of Northpond Ventures III, LP (\"Northpond Fund III\"), and Michael P. Rubin is the managing member of Northpond III LLC.  As a result, each of Northpond III LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":2805426,"source":{"system":"sec-edgar","filing":"0000950170-24-014000","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1867627/000095017024014000/ownership.xml","form_type":"4"}},{"id":1845460,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T17:36:33.000Z","date":"2023-06-22","kind":"sale","planned":false,"acquired":false,"shares":523503,"price":46.5,"value":24342889.5,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $46.44 to $46.63, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC. As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":166293,"source":{"system":"sec-edgar","filing":"0000899243-23-016413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924323016413/doc4.xml","form_type":"4"}},{"id":1845459,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T17:36:33.000Z","date":"2023-06-22","kind":"sale","planned":false,"acquired":false,"shares":1969368,"price":46.5,"value":91575612.0,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $46.44 to $46.63, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC. As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":633707,"source":{"system":"sec-edgar","filing":"0000899243-23-016413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924323016413/doc4.xml","form_type":"4"}},{"id":1864068,"issuer":{"id":15606,"kind":"organization","name":"Telesis Bio Inc.","symbol":"TBIO"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":3,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Short-Term Warrants","published_at":"2023-06-07T18:15:42.000Z","date":"2023-06-05","kind":"grant","planned":false,"acquired":true,"shares":1692549,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The number of shares of Common Stock underlying this warrant (together with the warrant described in footnote 3, the \"Warrants\") and the exercise price are subject to customary adjustments in the event of any stock split, stock dividend and/or certain other events involving the Issuer."},{"field":"shares","element":"transactionShares","label":"F5","text":"The number of shares of Common Stock underlying this warrant (together with the warrant described in footnote 3, the \"Warrants\") and the exercise price are subject to customary adjustments in the event of any stock split, stock dividend and/or certain other events involving the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"NPV I paid no additional purchase-price consideration to acquire the Warrants pursuant to the Purchase Agreement, as all purchase-price consideration thereunder was attributable to the Preferred Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"The number of shares of Common Stock underlying this warrant (together with the warrant described in footnote 3, the \"Warrants\") and the exercise price are subject to customary adjustments in the event of any stock split, stock dividend and/or certain other events involving the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares of Common Stock underlying this warrant and the exercise price are subject to customary adjustments in the event of any stock split, stock dividend and/or certain other events involving the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"NPV I acquired the Preferred Stock and each of the Warrants (defined below) pursuant to the redeemable convertible preferred stock and warrant purchase agreement, dated as of May 31, 2023, by and among NPV I, the Issuer and the other investors party thereto (the \"Purchase Agreement\"), and NPV I holds the Preferred Stock and the Warrants directly. Each of Northpond Ventures GP, LLC (\"NPV I GP\"), the general partner of NPV I, and Michael P. Rubin, the managing member of NPV I GP, may be deemed to be the beneficial owner of the Preferred Stock and the Warrants held by NPV I, as a result of such relationships. Each of the reporting persons disclaims beneficial ownership of the Preferred Stock and the Warrants held by NPV I, expect to the extent of its or his respective pecuniary interested therein."}],"balance_after":1692549,"derivative":{"exercise_price":2.5996,"exercise_date":"2023-06-05","expiration_date":"2025-06-05","underlying":"Common Stock","underlying_shares":1692549},"source":{"system":"sec-edgar","filing":"0001104659-23-068998","document":"tm2318055-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1850079/000110465923068998/tm2318055-1_4seq1.xml","form_type":"4"}},{"id":1864067,"issuer":{"id":15606,"kind":"organization","name":"Telesis Bio Inc.","symbol":"TBIO"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":3,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Long-Term Warrants","published_at":"2023-06-07T18:15:42.000Z","date":"2023-06-05","kind":"grant","planned":false,"acquired":true,"shares":3385097,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The number of shares of Common Stock underlying this warrant and the exercise price are subject to customary adjustments in the event of any stock split, stock dividend and/or certain other events involving the Issuer."},{"field":"shares","element":"transactionShares","label":"F4","text":"The number of shares of Common Stock underlying this warrant and the exercise price are subject to customary adjustments in the event of any stock split, stock dividend and/or certain other events involving the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"NPV I paid no additional purchase-price consideration to acquire the Warrants pursuant to the Purchase Agreement, as all purchase-price consideration thereunder was attributable to the Preferred Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The number of shares of Common Stock underlying this warrant and the exercise price are subject to customary adjustments in the event of any stock split, stock dividend and/or certain other events involving the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares of Common Stock underlying this warrant and the exercise price are subject to customary adjustments in the event of any stock split, stock dividend and/or certain other events involving the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"NPV I acquired the Preferred Stock and each of the Warrants (defined below) pursuant to the redeemable convertible preferred stock and warrant purchase agreement, dated as of May 31, 2023, by and among NPV I, the Issuer and the other investors party thereto (the \"Purchase Agreement\"), and NPV I holds the Preferred Stock and the Warrants directly. Each of Northpond Ventures GP, LLC (\"NPV I GP\"), the general partner of NPV I, and Michael P. Rubin, the managing member of NPV I GP, may be deemed to be the beneficial owner of the Preferred Stock and the Warrants held by NPV I, as a result of such relationships. Each of the reporting persons disclaims beneficial ownership of the Preferred Stock and the Warrants held by NPV I, expect to the extent of its or his respective pecuniary interested therein."}],"balance_after":3385097,"derivative":{"exercise_price":2.5996,"exercise_date":"2023-06-05","expiration_date":"2030-06-05","underlying":"Common Stock","underlying_shares":3385097},"source":{"system":"sec-edgar","filing":"0001104659-23-068998","document":"tm2318055-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1850079/000110465923068998/tm2318055-1_4seq1.xml","form_type":"4"}},{"id":1864066,"issuer":{"id":15606,"kind":"organization","name":"Telesis Bio Inc.","symbol":"TBIO"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":3,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Redeemable Convertible Preferred Stock","published_at":"2023-06-07T18:15:42.000Z","date":"2023-06-05","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":100,"value":8000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of shares of common stock, par value $0.0001 per share, of the Issuer (\"Common Stock\") deliverable upon conversion of each share of redeemable convertible preferred stock, par value $0.0001 per share, of the Issuer (the \"Preferred Stock\") is calculated for purposes of this Form 4 by dividing the \"Accrued Value\" of all Preferred Stock acquired by Northpond Ventures, LP (\"NPV I\") as reported in this Form 4 (which aggregate Accrued Value is currently $8.0 million) by a Conversion Price per share of Preferred Stock of $2.3633 (which is the Conversion Price per share currently in effect for the Preferred Stock)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(continued from Footnote 1) The Accrued Value is subject to increase from time to time for accrued and unpaid dividends on the Preferred Stock, and the Conversion Price is subject to customary antidilution adjustments, and each is further defined and described in the Certificate of Designation of the Preferred Stock that the Issuer filed with the Secretary of State of the State of Delaware on June 1, 2023. The Preferred Stock is convertible into Common Stock at any time at the election of NPV I and is redeemable at any time after June 5, 2030 at the election of either NPV I or the Issuer. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The number of shares of common stock, par value $0.0001 per share, of the Issuer (\"Common Stock\") deliverable upon conversion of each share of redeemable convertible preferred stock, par value $0.0001 per share, of the Issuer (the \"Preferred Stock\") is calculated for purposes of this Form 4 by dividing the \"Accrued Value\" of all Preferred Stock acquired by Northpond Ventures, LP (\"NPV I\") as reported in this Form 4 (which aggregate Accrued Value is currently $8.0 million) by a Conversion Price per share of Preferred Stock of $2.3633 (which is the Conversion Price per share currently in effect for the Preferred Stock)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(continued from Footnote 1) The Accrued Value is subject to increase from time to time for accrued and unpaid dividends on the Preferred Stock, and the Conversion Price is subject to customary antidilution adjustments, and each is further defined and described in the Certificate of Designation of the Preferred Stock that the Issuer filed with the Secretary of State of the State of Delaware on June 1, 2023. The Preferred Stock is convertible into Common Stock at any time at the election of NPV I and is redeemable at any time after June 5, 2030 at the election of either NPV I or the Issuer. The Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares of common stock, par value $0.0001 per share, of the Issuer (\"Common Stock\") deliverable upon conversion of each share of redeemable convertible preferred stock, par value $0.0001 per share, of the Issuer (the \"Preferred Stock\") is calculated for purposes of this Form 4 by dividing the \"Accrued Value\" of all Preferred Stock acquired by Northpond Ventures, LP (\"NPV I\") as reported in this Form 4 (which aggregate Accrued Value is currently $8.0 million) by a Conversion Price per share of Preferred Stock of $2.3633 (which is the Conversion Price per share currently in effect for the Preferred Stock)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"(continued from Footnote 1) The Accrued Value is subject to increase from time to time for accrued and unpaid dividends on the Preferred Stock, and the Conversion Price is subject to customary antidilution adjustments, and each is further defined and described in the Certificate of Designation of the Preferred Stock that the Issuer filed with the Secretary of State of the State of Delaware on June 1, 2023. The Preferred Stock is convertible into Common Stock at any time at the election of NPV I and is redeemable at any time after June 5, 2030 at the election of either NPV I or the Issuer. The Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares of common stock, par value $0.0001 per share, of the Issuer (\"Common Stock\") deliverable upon conversion of each share of redeemable convertible preferred stock, par value $0.0001 per share, of the Issuer (the \"Preferred Stock\") is calculated for purposes of this Form 4 by dividing the \"Accrued Value\" of all Preferred Stock acquired by Northpond Ventures, LP (\"NPV I\") as reported in this Form 4 (which aggregate Accrued Value is currently $8.0 million) by a Conversion Price per share of Preferred Stock of $2.3633 (which is the Conversion Price per share currently in effect for the Preferred Stock)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from Footnote 1) The Accrued Value is subject to increase from time to time for accrued and unpaid dividends on the Preferred Stock, and the Conversion Price is subject to customary antidilution adjustments, and each is further defined and described in the Certificate of Designation of the Preferred Stock that the Issuer filed with the Secretary of State of the State of Delaware on June 1, 2023. The Preferred Stock is convertible into Common Stock at any time at the election of NPV I and is redeemable at any time after June 5, 2030 at the election of either NPV I or the Issuer. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"NPV I acquired the Preferred Stock and each of the Warrants (defined below) pursuant to the redeemable convertible preferred stock and warrant purchase agreement, dated as of May 31, 2023, by and among NPV I, the Issuer and the other investors party thereto (the \"Purchase Agreement\"), and NPV I holds the Preferred Stock and the Warrants directly. Each of Northpond Ventures GP, LLC (\"NPV I GP\"), the general partner of NPV I, and Michael P. Rubin, the managing member of NPV I GP, may be deemed to be the beneficial owner of the Preferred Stock and the Warrants held by NPV I, as a result of such relationships. Each of the reporting persons disclaims beneficial ownership of the Preferred Stock and the Warrants held by NPV I, expect to the extent of its or his respective pecuniary interested therein."}],"balance_after":3385097,"derivative":{"exercise_price":2.3633,"exercise_date":"2023-06-05","underlying":"Common Stock","underlying_shares":3385097},"source":{"system":"sec-edgar","filing":"0001104659-23-068998","document":"tm2318055-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850079/000110465923068998/tm2318055-1_4seq1.xml","form_type":"4"}},{"id":2438028,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2022-01-11T20:18:29.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":1027978,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1027978},"source":{"system":"sec-edgar","filing":"0000899243-22-001631","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924322001631/doc4.xml","form_type":"4"}},{"id":2438027,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2022-01-11T20:18:29.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":2831520,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2831520},"source":{"system":"sec-edgar","filing":"0000899243-22-001631","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924322001631/doc4.xml","form_type":"4"}},{"id":2438026,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T20:18:29.000Z","date":"2022-01-11","kind":"purchase","acquired":true,"shares":355000,"price":14,"value":4970000.0,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":1382978,"source":{"system":"sec-edgar","filing":"0000899243-22-001631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924322001631/doc4.xml","form_type":"4"}},{"id":2438025,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T20:18:29.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":1027978,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":1027978,"source":{"system":"sec-edgar","filing":"0000899243-22-001631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924322001631/doc4.xml","form_type":"4"}},{"id":2438024,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T20:18:29.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":2831520,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":2831520,"source":{"system":"sec-edgar","filing":"0000899243-22-001631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924322001631/doc4.xml","form_type":"4"}},{"id":2542535,"issuer":{"id":115290,"kind":"organization","name":"IsoPlexis Corp","symbol":"ISO"},"owners":[{"id":134605,"kind":"organization","name":"Northpond Capital GP, LLC","position":1,"cik":"0001871669","reported_name":"Northpond Capital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134606,"kind":"organization","name":"Northpond Capital, L.P.","position":2,"cik":"0001871659","reported_name":"Northpond Capital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Redeemable Convertible Preferred Stock","published_at":"2021-10-14T16:24:44.000Z","date":"2021-10-12","kind":"exercise","acquired":false,"shares":130006,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held directly by Northpond Capital, LP (\"Northpond Capital\"). Northpond Capital GP, LLC (\"Northpond Capital GP\") is the general partner of Northpond Capital. Rubin is the managing member of Northpond Capital GP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1040048},"source":{"system":"sec-edgar","filing":"0001209191-21-060463","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1871669/000120919121060463/doc4.xml","form_type":"4"}},{"id":2542534,"issuer":{"id":115290,"kind":"organization","name":"IsoPlexis Corp","symbol":"ISO"},"owners":[{"id":134605,"kind":"organization","name":"Northpond Capital GP, LLC","position":1,"cik":"0001871669","reported_name":"Northpond Capital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134606,"kind":"organization","name":"Northpond Capital, L.P.","position":2,"cik":"0001871659","reported_name":"Northpond Capital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Redeemable Convertible Preferred Stock","published_at":"2021-10-14T16:24:44.000Z","date":"2021-10-12","kind":"exercise","acquired":false,"shares":191108,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Northpond Ventures, LP (\"Northpond\"). Northpond Ventures GP, LLC (\"Northpond GP\") is the general partner\nof Northpond. Michael P. Rubin (\"Rubin\") is the managing member of Northpond GP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1528864},"source":{"system":"sec-edgar","filing":"0001209191-21-060463","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1871669/000120919121060463/doc4.xml","form_type":"4"}},{"id":2542533,"issuer":{"id":115290,"kind":"organization","name":"IsoPlexis Corp","symbol":"ISO"},"owners":[{"id":134605,"kind":"organization","name":"Northpond Capital GP, LLC","position":1,"cik":"0001871669","reported_name":"Northpond Capital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134606,"kind":"organization","name":"Northpond Capital, L.P.","position":2,"cik":"0001871659","reported_name":"Northpond Capital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Redeemable Convertible Preferred Stock","published_at":"2021-10-14T16:24:44.000Z","date":"2021-10-12","kind":"exercise","acquired":false,"shares":309131,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Northpond Ventures, LP (\"Northpond\"). Northpond Ventures GP, LLC (\"Northpond GP\") is the general partner\nof Northpond. Michael P. Rubin (\"Rubin\") is the managing member of Northpond GP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2473048},"source":{"system":"sec-edgar","filing":"0001209191-21-060463","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1871669/000120919121060463/doc4.xml","form_type":"4"}},{"id":2542532,"issuer":{"id":115290,"kind":"organization","name":"IsoPlexis Corp","symbol":"ISO"},"owners":[{"id":134605,"kind":"organization","name":"Northpond Capital GP, LLC","position":1,"cik":"0001871669","reported_name":"Northpond Capital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134606,"kind":"organization","name":"Northpond Capital, L.P.","position":2,"cik":"0001871659","reported_name":"Northpond Capital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2021-10-14T16:24:44.000Z","date":"2021-10-12","kind":"exercise","acquired":false,"shares":287785,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Northpond Ventures, LP (\"Northpond\"). Northpond Ventures GP, LLC (\"Northpond GP\") is the general partner\nof Northpond. Michael P. Rubin (\"Rubin\") is the managing member of Northpond GP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2302280},"source":{"system":"sec-edgar","filing":"0001209191-21-060463","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1871669/000120919121060463/doc4.xml","form_type":"4"}},{"id":2542531,"issuer":{"id":115290,"kind":"organization","name":"IsoPlexis Corp","symbol":"ISO"},"owners":[{"id":134605,"kind":"organization","name":"Northpond Capital GP, LLC","position":1,"cik":"0001871669","reported_name":"Northpond Capital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134606,"kind":"organization","name":"Northpond Capital, L.P.","position":2,"cik":"0001871659","reported_name":"Northpond Capital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-14T16:24:44.000Z","date":"2021-10-12","kind":"purchase","acquired":true,"shares":1000000,"price":15,"value":15000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held directly by Northpond Capital, LP (\"Northpond Capital\"). Northpond Capital GP, LLC (\"Northpond Capital GP\") is the general partner of Northpond Capital. Rubin is the managing member of Northpond Capital GP."}],"balance_after":2080961,"source":{"system":"sec-edgar","filing":"0001209191-21-060463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1871669/000120919121060463/doc4.xml","form_type":"4"}},{"id":2542530,"issuer":{"id":115290,"kind":"organization","name":"IsoPlexis Corp","symbol":"ISO"},"owners":[{"id":134605,"kind":"organization","name":"Northpond Capital GP, LLC","position":1,"cik":"0001871669","reported_name":"Northpond Capital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134606,"kind":"organization","name":"Northpond Capital, L.P.","position":2,"cik":"0001871659","reported_name":"Northpond Capital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-14T16:24:44.000Z","date":"2021-10-12","kind":"exercise","acquired":true,"shares":1040048,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 40,913 shares of Common Stock issued per dividends accrued to but not including October 12, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held directly by Northpond Capital, LP (\"Northpond Capital\"). Northpond Capital GP, LLC (\"Northpond Capital GP\") is the general partner of Northpond Capital. Rubin is the managing member of Northpond Capital GP."}],"balance_after":1080961,"source":{"system":"sec-edgar","filing":"0001209191-21-060463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1871669/000120919121060463/doc4.xml","form_type":"4"}},{"id":2542529,"issuer":{"id":115290,"kind":"organization","name":"IsoPlexis Corp","symbol":"ISO"},"owners":[{"id":134605,"kind":"organization","name":"Northpond Capital GP, LLC","position":1,"cik":"0001871669","reported_name":"Northpond Capital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134606,"kind":"organization","name":"Northpond Capital, L.P.","position":2,"cik":"0001871659","reported_name":"Northpond Capital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-14T16:24:44.000Z","date":"2021-10-12","kind":"exercise","acquired":true,"shares":6304192,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series C Redeemable Convertible Preferred Stock, Series C-2 Redeemable Convertible Preferred Stock and Series D Redeemable Convertible Preferred Stock automatically converted on a one-for-8 basis into Common Stock upon the consummation of the Issuer's initial public offering. The preferred stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 423,378 shares of Common Stock issued per dividends accrued to but not including October 12, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Northpond Ventures, LP (\"Northpond\"). Northpond Ventures GP, LLC (\"Northpond GP\") is the general partner\nof Northpond. Michael P. Rubin (\"Rubin\") is the managing member of Northpond GP."}],"balance_after":6727570,"source":{"system":"sec-edgar","filing":"0001209191-21-060463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871669/000120919121060463/doc4.xml","form_type":"4"}},{"id":2564190,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Convertible Preferred Stock","published_at":"2021-09-20T21:19:52.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":454796,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":454796},"source":{"system":"sec-edgar","filing":"0000899243-21-036646","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321036646/doc4.xml","form_type":"4"}},{"id":2564189,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-09-20T21:19:52.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":867687,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":867687},"source":{"system":"sec-edgar","filing":"0000899243-21-036646","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321036646/doc4.xml","form_type":"4"}},{"id":2564188,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-09-20T21:19:52.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":1735388,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1735388},"source":{"system":"sec-edgar","filing":"0000899243-21-036646","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321036646/doc4.xml","form_type":"4"}},{"id":2564187,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T21:19:52.000Z","date":"2021-09-17","kind":"purchase","acquired":true,"shares":235000,"price":17,"value":3995000.0,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":3292871,"source":{"system":"sec-edgar","filing":"0000899243-21-036646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321036646/doc4.xml","form_type":"4"}},{"id":2564186,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T21:19:52.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":454796,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":3057871,"source":{"system":"sec-edgar","filing":"0000899243-21-036646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321036646/doc4.xml","form_type":"4"}},{"id":2564185,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T21:19:52.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":2603075,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":2603075,"source":{"system":"sec-edgar","filing":"0000899243-21-036646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321036646/doc4.xml","form_type":"4"}},{"id":2656170,"issuer":{"id":15606,"kind":"organization","name":"Telesis Bio Inc.","symbol":"TBIO"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2021-06-24T16:34:18.000Z","date":"2021-06-22","kind":"exercise","acquired":false,"shares":4160529,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4160529},"source":{"system":"sec-edgar","filing":"0000899243-21-025745","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321025745/doc4.xml","form_type":"4"}},{"id":2656169,"issuer":{"id":15606,"kind":"organization","name":"Telesis Bio Inc.","symbol":"TBIO"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-06-24T16:34:18.000Z","date":"2021-06-22","kind":"exercise","acquired":false,"shares":5214851,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5241851},"source":{"system":"sec-edgar","filing":"0000899243-21-025745","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321025745/doc4.xml","form_type":"4"}},{"id":2656168,"issuer":{"id":15606,"kind":"organization","name":"Telesis Bio Inc.","symbol":"TBIO"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-24T16:34:18.000Z","date":"2021-06-22","kind":"purchase","acquired":true,"shares":468750,"price":16,"value":7500000.0,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":9844130,"source":{"system":"sec-edgar","filing":"0000899243-21-025745","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321025745/doc4.xml","form_type":"4"}},{"id":2656167,"issuer":{"id":15606,"kind":"organization","name":"Telesis Bio Inc.","symbol":"TBIO"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-24T16:34:18.000Z","date":"2021-06-22","kind":"exercise","acquired":true,"shares":9375380,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":9375380,"source":{"system":"sec-edgar","filing":"0000899243-21-025745","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321025745/doc4.xml","form_type":"4"}}]}